Peripheral Liquid Embolic Agents

Global Peripheral Liquid Embolic Agents Market to Reach US$64.5 Million by 2030

The global market for Peripheral Liquid Embolic Agents estimated at US$42.8 Million in the year 2024, is expected to reach US$64.5 Million by 2030, growing at a CAGR of 7.1% over the analysis period 2024-2030. Tube Applicator / Inserter, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$38.4 Million by the end of the analysis period. Growth in the Tympanostomy Tubes segment is estimated at 9.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$11.7 Million While China is Forecast to Grow at 10.8% CAGR

The Peripheral Liquid Embolic Agents market in the U.S. is estimated at US$11.7 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$13.3 Million by the year 2030 trailing a CAGR of 10.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.6% and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Global Peripheral Liquid Embolic Agents Market - Key Trends & Drivers Summarized

What Makes Liquid Embolic Agents Effective in Complex Vascular Occlusions?

Peripheral liquid embolic agents are injectable compounds used to occlude blood vessels by solidifying in situ, blocking blood flow in abnormal or diseased vasculature. These agents are particularly effective in addressing high-flow or irregular vascular structures where coil deployment is insufficient. Their ability to fill tortuous or microvascular spaces makes them useful in treating arteriovenous malformations, bleeding tumors, and endoleaks.

Liquid embolics are delivered through microcatheters under fluoroscopic guidance. Once inside the target vessel, they undergo physical or chemical transitions—polymerization, precipitation, or solidification—forming a durable occlusion. Control over viscosity, flow, and setting time is critical to prevent non-target embolization and optimize treatment outcomes.

How Are Materials and Delivery Systems Improving Procedure Outcomes?

Liquid embolic agents now include formulations based on cyanoacrylate, ethylene vinyl alcohol, and other polymer-based systems. Improvements in radiopacity enhance procedural visibility. Some agents incorporate additives that reduce injection force and increase uniformity during deployment. Packaging innovations and prefilled syringes also reduce preparation time and support aseptic handling.

 

Delivery systems have advanced through development of dual-lumen catheters, reflux-resistant designs, and pressure-controlled injection devices. These tools provide interventionalists with higher accuracy and control during delivery. Efforts to reduce toxicity, improve biocompatibility, and enable selective penetration of microvessels are ongoing, especially in cases involving sensitive anatomy or pediatric patients.

Which Clinical Settings Are Driving Market Demand?

Hospitals and specialized interventional radiology centers are primary users of liquid embolics. Oncology centers use these agents to devascularize tumors before surgery or ablation. They are also critical in treating gastrointestinal hemorrhages, renal artery bleeding, and pelvic trauma. Use in neurovascular procedures is well-established, and application in peripheral vascular systems is expanding steadily.

The demand is growing in regions investing in advanced endovascular care. Countries with rising rates of non-communicable diseases, aging populations, and improving access to specialist interventions are driving growth. Integration of embolization into outpatient and day-care protocols is also contributing to higher procedural volumes and adoption of liquid agents.

Growth in the Peripheral Liquid Embolic Agents market is driven by several factors…

Growth in the peripheral liquid embolic agents market is driven by increasing incidence of peripheral vascular abnormalities, expanding applications in interventional oncology and trauma management, and continued development of advanced embolic formulations. Rising preference for minimally invasive embolization techniques in both emergency and elective procedures is supporting higher adoption.

Technological improvements in catheter-delivery systems, enhanced imaging compatibility, and wider availability of specialized interventional services are contributing to procedural efficiency and clinical confidence. Development of tailored embolic agents for high-flow lesions, fragile vasculature, and tumor vasculature further supports usage across diverse clinical scenarios. Growth in healthcare infrastructure and specialist training is expected to expand use globally.

SCOPE OF STUDY:

The report analyzes the Peripheral Liquid Embolic Agents market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Tube Applicator / Inserter, Tympanostomy Tubes); Material (Silicone Material, Fluoroplastic Material, Titanium Material, Stainless Steel Material); Application (Acute Otitis Media Application, Recurrent Otitis Media with Effusion Application); End-Use (Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Abbott Laboratories
• Acandis GmbH
• Balt
• Boston Medical Corporation
• Cardiva
• Cook Medical LLC
• Cerenovus (J&J)
• IMBiotechnologies Ltd.
• Johnson & Johnson
• Kaneka Corporation
• Medtronic plc
• Merit Medical Systems
• Meril Life Sciences Pvt. Ltd.
• MicroVention Inc. (Terumo)
• Penumbra, Inc.
• Rapid Medical
• Stryker Corporation
• Terumo Corporation
• Sirtex Medical Limited

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.